Nse trader, mcx traders, ncdex traader ,stock futer trader ,options trading
Friday, 24 March 2017
sunpharma news
Sun Pharmaceutical Industries Ltd SUN.NS
* Says validation of regulatory filing of tildrakizumab with the european medicines agency (EMA) by Almirall.
* Tildrakizumab is an investigational IL-23P19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis.
* Filing includes efficacy, safety data from pivotal phase III clinical trials that included over 1,800 patients Source text - Further company coverage: SUN.NS
Followers
Stock market updates
buy LT 3800-3810 stop loss 3780 target 3835/3900/3950
-
buy LT 3800-3810 stop loss 3780 target 3835/3900/3950
-
At Nagpur market , Soybean Plant ended lower at Rs. 3250-3300 per quintal, lower by 1.49 per cent as compared to previous day. Soybean Mandi...
-
buy bank nifty@49200 sl 49000 target 49400/49600/49800 Recommendation: Buy Bank Nifty @ 49,200 Stop Loss (SL): 49,000 Targets: 1st Target: ...